A Phase II Study of Capecitabine plus Paclitaxel Combination Chemotherapy in Patients with Metastatic Breast Cancer
Phase 2
- Conditions
- Metastatic Breast Cancer
- Registration Number
- JPRN-UMIN000000869
- Lead Sponsor
- KBCSG (Kinki Breast Cancer Study Group)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 42
Inclusion Criteria
Not provided
Exclusion Criteria
1) Have Capecitabine before 2) Have Paclitaxel for metastatic lesion before 3) Hypersensitivity to drugs 4) active double cancer 5) severe complication 6) in pregnancy or lactation 7) Symptomatic brain metastasis
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie capecitabine-paclitaxel synergy in metastatic breast cancer?
How does capecitabine plus paclitaxel compare to standard chemotherapy regimens in HER2-negative metastatic breast cancer patients?
What biomarkers correlate with response to capecitabine-paclitaxel combination therapy in metastatic breast cancer?
What are the most common adverse events associated with capecitabine-paclitaxel treatment in metastatic breast cancer patients?
How do capecitabine-paclitaxel combination strategies compare to other taxane-based regimens in metastatic breast cancer treatment?